Abstract
One of the most extensively studied mechanisms of drug resistance involves the drug efflux pump P-glycoprotein (Pgp). The availability of radiolabeled substrates of Pgp such as 99mTc-MIBI and analogous 99mTc-labeled agents allows the clinical assessment of Pgp function in cancer patients. The consistency of the results from different institutions and trials strongly support the clinical application of this imaging technique for individual tailoring of chemotherapeutic regimens and for designing clinical trials with Pgp modulators.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance, Neoplasm*
-
Humans
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / metabolism
-
Neoplasms / diagnostic imaging
-
Neoplasms / drug therapy
-
Neoplasms / metabolism*
-
Organotechnetium Compounds
-
Radiopharmaceuticals* / pharmacokinetics
-
Technetium Tc 99m Sestamibi* / pharmacokinetics
-
Tomography, Emission-Computed, Single-Photon*
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Antineoplastic Agents
-
Organotechnetium Compounds
-
Radiopharmaceuticals
-
Technetium Tc 99m Sestamibi